ReoStem TECHNOLOGY

A new paradigm in allogenic stem cells

You are here:

A new benchmark:
Cell lines established in the year 2000 from a single source

ReoStem is a unique, replicable, clinical-stage technology platform for the generation of allogenic stem cells. It covers all stages of cell culture from derivation, expansion, and establishment of cell lines to the preparation of ready-to-use allogenic stem cell products.

ReoStem technology produces cell lines which are capable of differentiating into almost all the cell types of the body. The suppression of immunogenic genes make universality an important feature of these cell lines. Greater than 90% viability is routinely achieved in the ready-to-use format when kept under temperature-controlled conditions for more than 10 years. There is no contamination with any animal products, bacteria or fungi. Microarray data show that ReoStem cells are genetically stable.

The resultant products have genomic stability and universal acceptability.

CELL CULTUREMETHODOLOGY

The cell lines were derived from a single, expendable fertilized ovum in the year 2000 from a regular IVF cycle undertaken with due consent. This novel technology was subsequently patented and published.

UNIQUE PROFILE of ReoStem

ReoStem is an allogenic stem cell platform. It combines the following features:

null

Ethically derived from a
pre-morula
fertilized ovum

Ethically derived from a
pre-morula
fertilized ovum

The cell lines are ethically derived from a very early stage spare, fertilized ovum from an IVF cycle after due consent.

null

No animal product
contamination

No animal product
contamination

No animal products are used either in the primary culture media or as growth factors. There are no feeder cells. The cells are grown in suspension and their purity is maintained.

null

Allogenic
stem cell lines

Allogenic
stem cell lines

ReoStem technology has two cell lines- one is predominantly neuronal and the other is predominantly non-neuronal.

null

Cell lines from
a single source

Cell lines from
a single source

Cell lines currently in use derived from a single source in the year 2000 and have maintained full cell viability and stability

null

Chromosomally
stable

Chromosomally
stable

The cell lines demonstrate long-term chromosomal stability based on over 19 years of expansion and observation since the year 2000.

null

Universally
acceptable

Universally
acceptable

The technology preserves the purity of the cell lines and maintains the absence of surface antigens. Thus, the cells need not be matched to the recipient and are applicable universally.

null

No immunosuppression
required

No immunosuppression
required

The cells do not trigger an immune reaction due to the absence of HLA antigens on the cell surface. Therefore, no immune-suppressants are required to be co-administered with the cells/ treatment.

null

No teratoma
or tumour
formation

No teratoma
or tumour
formation

Safety and efficacy studies and longitudinal observation over a time frame of over 15 years has confirmed safety of the technology. No adverse events, teratomas or tumours have been observed.

null

Ready-to-use
products

Ready-to-use
products

The products are available in pre-packaged form ready for clinical use without the need for any further processing.

null

Long
shelf life

Long
shelf life

The ready-to-use product has a shelf life of 10 years when stored under specified temperature conditions.

UNDERSTANDING

ReoStem TECHNOLOGY

ReoStem platform has derived its cell lines from a single, expendable fertilized ovum taken from a natural IVF cycle with full and informed consent of the donor.

The cells are cultured in an animal product-free media in suspension. The number of cells greatly increase after incubation.

Expansion and Controlled differentiation

Post incubation, the cells are expanded and selectively primed to create two cell lines, enriched for neuronal and non-neuronal precursors, respectively. Uniquely, ReoStem permits incubation and expansion in a cyclic process.

Preparation of ready to use products.

These cells can either be stored or re-incubated. The cells are stored at -18°C to -22°C. The cells are centrifuged and re-suspended in clinical grade normal saline. This is the ready to use product.

Storage of ready-to-use Products.

The ready to use product should be stored at -18°C to -22°C. Its viability is maintained for more than 10 years.

The end use is for clinical application. The product needs to be thawed before use.